Health & Fitness
Health and Fitness
Health and Fitness
Thu, September 3, 2009
Wed, September 2, 2009
Tue, September 1, 2009
Corporate Profile, LLC: Access Pharmaceuticals CEO Interviewed on CorporateProfile.com
NEW YORK, NY--(Marketwire - September 1, 2009) - Corporate Profile, LLC announced today that Access Pharmaceuticals, Inc. (
The video can be viewed at: [ www.corporateprofile.com ].
About Access Pharmaceuticals
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.
For additional information, please visit [ www.accesspharma.com ].
About CorporateProfile.com
CorporateProfile.com is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in the unique platform for investors to receive today's hottest tips and market info.
From New York's top models straight to Wall Street, Corporate Profile's financial models are on the street and in the markets, interviewing CEOs, investment managers, and market gurus about what really drives returns.
Safe Harbor Disclaimer
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation.
